期刊文献+

辅酶Q_(10)纳米裸晶的制备及表征 被引量:1

Preparation and characterization of Coenzyme Q_(10) naked nanocrystal
下载PDF
导出
摘要 目的制备不含稳定剂且稳定存在的辅酶Q10(coenzyme Q10,CoQ10)纳米裸晶。方法分别以沉降法和逆向沉降法制备纳米裸晶,并运用激光粒度仪、zeta电位仪和透射电镜(transmission electron microscope,TEM)考察制剂的理化性质。结果确定最终处方工艺,得到粒径范围在80~700 nm内的纳米裸晶,其中粒径为(82.6±5.4)、(118.2±14.5)、(388.6±19.8)和(675.1±53.4)nm制剂的zeta电位分别为-(34.20±0.47)、-(29.23±0.34)、-(17.68±0.37)和-(6.54±1.78)mV,透射电镜观察纳米裸晶呈圆球状。结论成功制备了不含稳定剂的CoQ10纳米裸晶。 Objective To prepare stable CoQ10 naked nanocrystal without any surfactant or polymer. Methods CoQ10 naked nanocrystals were prepared by precipitation method and anti-precipitation method. The laser light scattering technique, zeta potential analyzer and TEM were employed to study the physicochemical properties of naked nanocrystal. Results Naked nanocrystals with different sizes ranging from 80 nm to 700 nm were prepared. The zeta potential of nanocrystals with the size of(82.6 ± 5.4)、(118.2 ± 14.5)、(388.6 ± 19.8) and(675.1 ± 53.4) nm were-(34.20 ± 0.47)、-(29.23 ± 0.34)、-(17.68 ± 0.37) and-(6.54 ± 1.78) mV, respectively. TEM images show that nanocrystals were spherical. Conclusions Through optimizing the formulations and preparation conditions, CoQ10 naked nanocrystals were successfully prepared without stabilizer.
出处 《中国药剂学杂志(网络版)》 2014年第3期73-80,共8页 Chinese Journal of Pharmaceutics:Online Edition
关键词 药剂学 纳米裸晶 沉降法 逆向沉降法 CoQ10 粒径 pharmaceutics naked nanocrystal precipitation method anti-precipitation method coenzyme Q10 size
  • 相关文献

参考文献9

  • 1王范,孙姣,邓意辉.辅酶Q_(10)纳米混悬剂的粒径和溶解度之间的关系[J].沈阳药科大学学报,2010,27(12):933-939. 被引量:1
  • 2陈莉,汤忞,陆伟根.纳米混悬剂粒径稳定性及其控制策略[J].世界临床药物,2010,31(4):245-249. 被引量:26
  • 3艾萍,金义光,王林校.药物传送中的纳米混悬液[J].国外医学(药学分册),2005,32(1):61-63. 被引量:9
  • 4Indrajit Ghosh,Sonali Bose,Radha Vippagunta,Ferris Harmon.Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth[J]. International Journal of Pharmaceutics . 2011 (1)
  • 5Hai-Xia Zhang,Jie-Xin Wang,Zhi-Bing Zhang,Yuan Le,Zhi-Gang Shen,Jian-Feng Chen.Micronization of atorvastatin calcium by antisolvent precipitation process[J]. International Journal of Pharmaceutics . 2009 (1)
  • 6Ji-Yao Zhang,Zhi-Gang Shen,Jie Zhong,Ting-Ting Hu,Jian-Feng Chen,Zhong-Qing Ma,Jimmy Yun.Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants[J]. International Journal of Pharmaceutics . 2006 (1)
  • 7X. Zhang,Q. Xia,N. Gu.Preparation of All-Trans Retinoic Acid Nanosuspensions Using a Modified Precipitation Method[J]. Drug Development and Industrial Pharmacy . 2006 (7)
  • 8Sergio Galindo-Rodriguez,Eric Allémann,Hatem Fessi,Eric Doelker.Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods[J]. Pharmaceutical Research . 2004 (8)
  • 9R.H Müller,C Jacobs,O Kayser.Nanosuspensions as particulate drug formulations in therapy[J]. Advanced Drug Delivery Reviews . 2001 (1)

二级参考文献40

  • 1陈华,刘亚青.超临界流体快速膨胀法制备微细颗粒[J].化工科技,2006,14(6):44-48. 被引量:1
  • 2Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs [J]. Int J Pharm, 2004, 284 (1-2): 109-122.
  • 3Duchene D, Bochot A, Yu SC, et al. Cyclodextrins and emulsions[J].Int J Pharm, 2003, 266 (1-2) : 85-90.
  • 4Suitthimeathegorn O, Jaitely V, Florence AT. Novel anhydrous emulsions: formulation as controlled release vehicles [J]. Int J Pharm, 2005, 298 (2): 367-371.
  • 5Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future[J]. Adv Drug Deliv Rev, 2001, 47 (1) : 3-19.
  • 6Fakes MG, Vakkalagadda B J, Qian F, et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches [J]. Int J Pharm, 2009, 370(1-2): 167-174.
  • 7Moschwitzer J, Achleitner G, Pomper H, et al. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology [J]. Eur J Pharm Biopharm, 2004, 58 (3) : 615-619.
  • 8Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery [J3. Int J Pharm, 2009, 365 (1-2) : 162-169.
  • 9Mishra PR, Al Shaal L, Muller RH, et al. Production and characterization of Hesperetin nanosuspensions for dermal delivery [J]. Int J Pharm, 2009, 371 (1-2): 182-189.
  • 10Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen [J]. Eur J Pharm Sci, 2002, 16 (1-2): 53-61.

共引文献33

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部